Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(5):673–677. doi: 10.1038/bjc.1997.120

Increase in the circulating level of hepatocyte growth factor in gastric cancer patients.

T Taniguchi 1, M Kitamura 1, K Arai 1, Y Iwasaki 1, Y Yamamoto 1, A Igari 1, M Toi 1
PMCID: PMC2063328  PMID: 9043023

Abstract

We measured serum concentrations of hapatocyte growth factor (HGF) in patients with gastric cancer and compared these with the histological findings and conventional tumour markers, including CEA, CA19-9 and CA125, for evaluation of the significance of serum HGF levels as a tumour marker. The HGF levels were measured by an enzyme-linked immunosorbent assay (ELISA) system. The average levels of serum HGF in 89 healthy control subjects, 104 patients with primary gastric cancer and 15 patients with recurrent gastric cancer were 0.31 +/- 0.11 ng ml(1), 0.42 +/- 0.50 ng ml(-1) and 0.92 +/- 0.39 ng ml(-1) respectively. The average level in patients with recurrent disease was significantly higher than in healthy control subjects and in primary cancer patients (P< 0.001 and P< 0.003 respectively). Of 104 patients with primary gastric cancer, 35 (33.7%) showed an aberrant increase in the circulating level of HGF. The increased HGF levels were significantly associated with the degrees of histological tumour invasion and venous invasion. Of 15 patients with recurrent gastric cancer, 14 (93.3%) showed an aberrant increase. No correlation was found between serum HGF levels and CEA levels, CA19-9 levels and CA125 levels. However, the rate of the aberrant increase in HGF levels was significantly higher than that of any other tumour markers, including CEA, CA19-9 and CA125, in primary gastric cancer patients. In conclusion, the circulating levels of HGF were elevated in approximately one-third of patients with primary gastric cancer, particularly in those with high grades of histological tumour invasion and venous invasion, and frequently in patients with distant metastases, suggesting that HGF might play important roles in the tumour progression of gastric cancer. Furthermore, serum HGF levels may be of value as a tumour marker in patients with gastric cancer.

Full text

PDF
673

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Di Renzo M. F., Narsimhan R. P., Olivero M., Bretti S., Giordano S., Medico E., Gaglia P., Zara P., Comoglio P. M. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene. 1991 Nov;6(11):1997–2003. [PubMed] [Google Scholar]
  2. Dignass A. U., Lynch-Devaney K., Podolsky D. K. Hepatocyte growth factor/scatter factor modulates intestinal epithelial cell proliferation and migration. Biochem Biophys Res Commun. 1994 Jul 29;202(2):701–709. doi: 10.1006/bbrc.1994.1987. [DOI] [PubMed] [Google Scholar]
  3. Eagles G., Warn A., Ball R. Y., Baillie-Johnson H., Arakaki N., Daikuhara Y., Warn R. M. Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Br J Cancer. 1996 Feb;73(3):377–381. doi: 10.1038/bjc.1996.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Foekens J. A., Look M. P., Peters H. A., van Putten W. L., Portengen H., Klijn J. G. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751–756. doi: 10.1093/jnci/87.10.751. [DOI] [PubMed] [Google Scholar]
  5. Grant D. S., Kleinman H. K., Goldberg I. D., Bhargava M. M., Nickoloff B. J., Kinsella J. L., Polverini P., Rosen E. M. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1937–1941. doi: 10.1073/pnas.90.5.1937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Guadagni F., Roselli M., Amato T., Cosimelli M., Perri P., Casale V., Carlini M., Santoro E., Cavaliere R., Greiner J. W. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res. 1992 Mar 1;52(5):1222–1227. [PubMed] [Google Scholar]
  7. Hildenbrand R., Dilger I., Hörlin A., Stutte H. J. Urokinase and macrophages in tumour angiogenesis. Br J Cancer. 1995 Oct;72(4):818–823. doi: 10.1038/bjc.1995.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kondo S., Shinomura Y., Kanayama S., Higashimoto Y., Kiyohara T., Yasunaga Y., Kitamura S., Ueyama H., Imamura I., Fukui H. Helicobacter pylori increases gene expression of hepatocyte growth factor in human gastric mucosa. Biochem Biophys Res Commun. 1995 May 25;210(3):960–965. doi: 10.1006/bbrc.1995.1750. [DOI] [PubMed] [Google Scholar]
  9. Kuniyasu H., Yasui W., Kitadai Y., Yokozaki H., Ito H., Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992 Nov 30;189(1):227–232. doi: 10.1016/0006-291x(92)91548-5. [DOI] [PubMed] [Google Scholar]
  10. Kuniyasu H., Yasui W., Yokozaki H., Kitadai Y., Tahara E. Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer. 1993 Aug 19;55(1):72–75. doi: 10.1002/ijc.2910550114. [DOI] [PubMed] [Google Scholar]
  11. Ming S. C. Gastric carcinoma. A pathobiological classification. Cancer. 1977 Jun;39(6):2475–2485. doi: 10.1002/1097-0142(197706)39:6<2475::aid-cncr2820390626>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  12. Naka D., Ishii T., Shimomura T., Hishida T., Hara H. Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes. Exp Cell Res. 1993 Dec;209(2):317–324. doi: 10.1006/excr.1993.1316. [DOI] [PubMed] [Google Scholar]
  13. Nakamura T., Nawa K., Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984 Aug 16;122(3):1450–1459. doi: 10.1016/0006-291x(84)91253-1. [DOI] [PubMed] [Google Scholar]
  14. Naldini L., Tamagnone L., Vigna E., Sachs M., Hartmann G., Birchmeier W., Daikuhara Y., Tsubouchi H., Blasi F., Comoglio P. M. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992 Dec;11(13):4825–4833. doi: 10.1002/j.1460-2075.1992.tb05588.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Naldini L., Vigna E., Bardelli A., Follenzi A., Galimi F., Comoglio P. M. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem. 1995 Jan 13;270(2):603–611. doi: 10.1074/jbc.270.2.603. [DOI] [PubMed] [Google Scholar]
  16. Rosen E. M., Carley W., Goldberg I. D. Scatter factor regulates vascular endothelial cell motility. Cancer Invest. 1990;8(6):647–650. doi: 10.3109/07357909009018936. [DOI] [PubMed] [Google Scholar]
  17. Seslar S., Nakamura T., Byers S. Tumor-stroma interactions and stromal cell density regulate hepatocyte growth factor protein levels: a role for transforming growth factor-beta activation. Endocrinology. 1995 May;136(5):1945–1953. doi: 10.1210/endo.136.5.7720642. [DOI] [PubMed] [Google Scholar]
  18. Tajima H., Matsumoto K., Nakamura T. Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp Cell Res. 1992 Oct;202(2):423–431. doi: 10.1016/0014-4827(92)90095-p. [DOI] [PubMed] [Google Scholar]
  19. Tamura M., Arakaki N., Tsubouchi H., Takada H., Daikuhara Y. Enhancement of human hepatocyte growth factor production by interleukin-1 alpha and -1 beta and tumor necrosis factor-alpha by fibroblasts in culture. J Biol Chem. 1993 Apr 15;268(11):8140–8145. [PubMed] [Google Scholar]
  20. Taniguchi T., Toi M., Inada K., Imazawa T., Yamamoto Y., Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res. 1995 Sep;1(9):1031–1034. [PubMed] [Google Scholar]
  21. Taniguchi T., Toi M., Tominaga T. Rapid induction of hepatocyte growth factor by heparin. Lancet. 1994 Aug 13;344(8920):470–470. doi: 10.1016/s0140-6736(94)91797-3. [DOI] [PubMed] [Google Scholar]
  22. Wobbes T., Thomas C. M., Segers M. F., Nagengast F. M. Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992 Apr 15;69(8):2036–2041. doi: 10.1002/1097-0142(19920415)69:8<2036::aid-cncr2820690805>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  23. Yamashita J., Ogawa M., Yamashita S., Nomura K., Kuramoto M., Saishoji T., Shin S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 1994 Apr 1;54(7):1630–1633. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES